Insider

CME Group Inc.

CME Financials · 1 analysis

CME reported $1.7B in revenue (+13.0% YoY), compared with a +10.9% median across covered Financials peers. 1 open-market insider purchase recorded; 6 insider sales recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Company history

October 2026

CME GROUP INC.: 12 recorded developments from 2 official sources in 2026-10.

  • 2026-10-21: On October 21, 2026, CME Group Inc. issued a press release reporting its financial results for the quarter ended September 30, 2026, attached as Exhibit 99.1. Source
  • 2026-10-21: CME Group's total revenues were 1,737.3 (dollars in millions) in the quarter ended September 30, 2026, versus 1,537.6 a year earlier; nine-month revenues were 5,323.6 versus 4,871.9. Source
  • 2026-10-21: CME Group's operating income was 1,141.4 (dollars in millions) in the quarter ended September 30, 2026, versus 972.6 in the 2025 quarter. Source
  • 2026-10-21: CME Group's net income was 1,036.9 (dollars in millions) in the quarter ended September 30, 2026, versus 908.0 in the 2025 quarter. Source
  • 2026-10-21: CME Group's diluted earnings per share were 2.89 in the quarter ended September 30, 2026, versus 2.49 in the 2025 quarter. Source
  • 2026-10-21: CME Group's clearing and transaction fees were 1,378.1 (dollars in millions) in the quarter ended September 30, 2026, versus 1,227.9 a year earlier; market data and information services were 243.1 versus 202.5. Source
  • 2026-10-21: CME Group's total expenses were 595.9 (dollars in millions) in the quarter ended September 30, 2026, versus 565.0 a year earlier. Source
  • 2026-10-21: The press release includes non-GAAP revenues, expenses, operating income, net income and earnings per share, with a reconciliation to the comparable GAAP measures. Source
  • 2026-10-21: CME Group's adjusted operating income was 1,205.5 (dollars in millions) in the quarter ended September 30, 2026, versus 1,051.0 in the 2025 quarter. Source
  • 2026-10-21: CME Group's adjusted net income was 1,083.9 (dollars in millions) in the quarter ended September 30, 2026, versus 978.4 in the 2025 quarter. Source
  • 2026-10-21: CME Group's adjusted diluted earnings per share were 3.02 in the quarter ended September 30, 2026, versus 2.68 in the 2025 quarter. Source
  • 2026-10-21: CME Group's energy ADV was 2,665 thousand contracts in 3Q 2026 versus 2,295 thousand in 3Q 2025; agricultural commodities ADV was 2,022 thousand versus 1,712 thousand. Source

September 2026

CME GROUP INC.: 7 recorded developments from 5 official sources in 2026-09.

  • Summary: S (open market or private sale): 1 transaction(s) on 2026-09-14, 500 disposed, total value 140,055 USD at a weighted average price of 280.11 USD; owned after the last one: 17,916 Source
  • 2026-09-16: Units to be sold: 388; aggregate market value: 106102.48 USD; units outstanding: 359576125 Source
  • 2026-09-25: CME Group Inc. certifies that none of the authorized shares of Series G Non-Voting Convertible Preferred Stock are outstanding and none will be issued. Source
  • 2026-09-25: On September 24, 2026, CME Group Inc. filed a certificate of elimination with the Secretary of State of the State of Delaware which, effective upon filing, eliminated from the Company’s certificate of incorporation all matters set forth in the certificate of designations with respect to Source
  • 2026-09-25: No shares of the Series G Preferred Stock were issued and outstanding at the time of the filing of the certificate of elimination. Source
  • 2026-09-25: A copy of the certificate of elimination is filed as Exhibit 3.1 to this report and incorporated herein by reference. Source
  • 2026-09-28: Summary: P (open market or private purchase): 1 transaction(s) on 2026-09-25, 292.55 acquired, total value 78,625.74 USD at a weighted average price of 268.76 USD; owned after the last one: 263,288.642 Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 23, 2026. SEC

LatestEarlierChange
Revenue quarter$1.7B$1.5B+13.0%
Operating income quarter$1.1B$973M+17.4%
Net income quarter$1B$908M+14.2%
Diluted EPS quarter$2.89$2.49+16.1%
Operating cash flow year to date$3.3B$3.1B+4.8%
Cash and cash equivalents balance$2.2B$4.4B-50.2%

Next results expected around January 22, 2027 (estimate: the quarter ending about December 30, 2026 plus the 23 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

1.5Q4 '24*62.1%1.6Q1 '2567.5%1.7Q2 '2566.7%1.5Q3 '2563.3%1.6Q4 '25*61.8%1.9Q1 '2669.7%1.7Q2 '2664.9%1.7Q3 '2665.7%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 39 covered companies in Financials (median revenue change +10.9% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
CME Group Inc. CME$1.7B+13.0%65.7%
Berkshire Hathaway Inc BRK-B$74.3B+16.6%—
Jpmorgan Chase & Co. JPM$50.2B+8.1%—
Visa Inc. V$45.9B+14.8%61.2%
Bank of America Corp BAC$30B+3.2%—
Progressive Corp PGR$23.2B+3.0%—
Wells Fargo & Company WFC$21.9B+2.0%—

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
September 9, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 9, 2026Daniel G KayeSale notice filed532$304.17$161,818SEC
November 2, 2026Julie WinklerSale notice filed10,079$305.15$3,075,607SEC
November 2, 2026Howard J SiegelSale notice filed2,000$303.00$606,000SEC
October 27, 2026Sunil CutinhoSale notice filed5,000$298.70$1,493,500SEC
October 22, 2026Martin J GepsmanSale notice filed400$302.50$121,000SEC
September 25, 2026William R ShepardPurchase293$268.76$78,626SEC
September 16, 2026Jonathan MarcusPlanned sale 10b5-1 plan388—$106,102SEC
September 14, 2026Elizabeth A CookSale500$280.11$140,055SEC
September 14, 2026Elizabeth Anne Cook TrustPlanned sale500—$140,053SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock30,149,084$7,898,457,117-1.4%Q3 2026
State Street16,228,031$4,251,419,561-0.7%Q3 2026
Geode Capital Management9,392,678$2,463,575,042+1.3%Q3 2026
Norges Bank (Norway's sovereign fund)4,820,646$1,064,543,256—Q2 2026
Wellington Management4,057,047$1,062,865,174+123.4%Q3 2026
Two Sigma Investments2,413,750$632,354,225-0.3%Q3 2026
Capital Research Global Investors1,923,170$503,832,077+61.1%Q3 2026
Fidelity (FMR)1,375,044$360,234,154+3.9%Q3 2026
D. E. Shaw & Co.1,167,354$305,823,401-11.8%Q3 2026
Citadel Advisors1,030,728$270,030,121-31.5%Q3 2026
Millennium Management494,017$129,422,574-58.7%Q3 2026
Renaissance Technologies474,609$124,338,066-30.2%Q3 2026
Soros Fund Management30,028$7,866,7350.0%Q3 2026
T. Rowe Price3,107,487$814,100+48.8%Q3 2026
Baupost Group (Seth Klarman)685,435$179,570+10.7%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.